The ITN develops and conducts clinical studies of
immune tolerance therapies — highly targeted treatments designed to prevent disease - causing immune responses, without compromising the natural protective properties of the immune system.
The mission of the ITN is the development of new
immune tolerance therapies — highly specific treatments that reprogram the immune system to inhibit disease - causing immune responses while keeping beneficial, disease - fighting immune responses intact.
Not exact matches
Some people, for example, undergo an intensive treatment called
immune tolerance induction
therapy, which involves regular intravenous administration of coagulation factors.
The latest study builds off of work Kawai and his colleagues began fourteen years ago, when they launched the first clinical trial that attempted to use bone marrow to induce
immune tolerance for kidney recipients, to avoid the sometimes dangerous side effects of life - long immosuppressive
therapy.
In the last decade, Foxp3 + Treg cells have raised the hope for novel cell - based
therapies to achieve
tolerance in clinical settings of unwanted
immune responses such as autoimmunity and graft rejection.
According to Bluestone, «The
Immune Tolerance Network hopes this breakthrough will act as a launch pad for further advances that will allow us to free transplant recipients from the
immune suppressive
therapies.»
Moreover, the correct nutritional management of dogs with cancer can also enhance the function of the
immune system, which plays a critical role in modulating and controlling cancer growth, as well as the
tolerance of and response to cancer
therapy.